By integrating nuclease-inactivated CRISPR-associated protein 9 (Cas9) with a transcriptional activator, the CRISPR/dCas9 system can harness a tumor cell's own genetic machinery to synthesize biologically active GSDM proteins, thereby ensuring a continuous internal supply. This evidence concerns the gene GSDMA and neoplasm.